TWI841523B - 治療及／或預防光化性角化症之方法 - Google Patents

治療及／或預防光化性角化症之方法 Download PDF

Info

Publication number
TWI841523B
TWI841523B TW107108242A TW107108242A TWI841523B TW I841523 B TWI841523 B TW I841523B TW 107108242 A TW107108242 A TW 107108242A TW 107108242 A TW107108242 A TW 107108242A TW I841523 B TWI841523 B TW I841523B
Authority
TW
Taiwan
Prior art keywords
square centimeters
affected area
days
administered
patent application
Prior art date
Application number
TW107108242A
Other languages
English (en)
Chinese (zh)
Other versions
TW201842913A (zh
Inventor
魯道夫 關
耀南 劉
伊道格拉斯 克拉莫
大衛 卡勒
榮生 方
Original Assignee
美商Ａｔｎｘ特殊目的實體公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI841523(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商Ａｔｎｘ特殊目的實體公司 filed Critical 美商Ａｔｎｘ特殊目的實體公司
Publication of TW201842913A publication Critical patent/TW201842913A/zh
Application granted granted Critical
Publication of TWI841523B publication Critical patent/TWI841523B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107108242A 2017-03-10 2018-03-12 治療及／或預防光化性角化症之方法 TWI841523B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
US62/469,889 2017-03-10

Publications (2)

Publication Number Publication Date
TW201842913A TW201842913A (zh) 2018-12-16
TWI841523B true TWI841523B (zh) 2024-05-11

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107108242A TWI841523B (zh) 2017-03-10 2018-03-12 治療及／或預防光化性角化症之方法

Country Status (23)

Country Link
US (3) US10617693B2 (https=)
EP (2) EP3592355B1 (https=)
JP (3) JP7502863B2 (https=)
KR (2) KR20240090837A (https=)
CN (1) CN110891575A (https=)
AU (2) AU2018231144B2 (https=)
BR (1) BR112019018687A2 (https=)
CA (1) CA3055938A1 (https=)
DK (1) DK3592355T3 (https=)
ES (1) ES3060528T3 (https=)
FI (1) FI3592355T3 (https=)
HR (1) HRP20260155T1 (https=)
IL (1) IL269182B2 (https=)
LT (1) LT3592355T (https=)
MX (2) MX387658B (https=)
NZ (1) NZ757105A (https=)
PL (1) PL3592355T3 (https=)
PT (1) PT3592355T (https=)
RS (1) RS67713B1 (https=)
SI (1) SI3592355T1 (https=)
TW (1) TWI841523B (https=)
WO (1) WO2018165647A1 (https=)
ZA (1) ZA202100106B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN117599189A (zh) * 2018-03-07 2024-02-27 慧源Spv公司 用于治疗过度增殖性皮肤障碍的组合物和方法
JP7296945B2 (ja) * 2018-03-28 2023-06-23 テルモ株式会社 医療デバイス
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
JP2024506240A (ja) * 2021-01-21 2024-02-13 サーナオミクス インコーポレイテッド 皮膚がんの治療のための組成物および方法
WO2025077886A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
WO2008144045A1 (en) 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
SI2378876T1 (sl) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 BUFFALO, N.Y Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) Kinex Pharmaceuticals VOL1 July 2014 1-2

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
KR20190141661A (ko) 2019-12-24
DK3592355T3 (da) 2026-02-16
IL269182B2 (en) 2023-11-01
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
KR20240090837A (ko) 2024-06-21
AU2018231144B2 (en) 2023-12-21
JP2023015269A (ja) 2023-01-31
AU2024201828A1 (en) 2024-05-02
LT3592355T (lt) 2026-02-25
JP2025029010A (ja) 2025-03-05
US20180256589A1 (en) 2018-09-13
JP2020510042A (ja) 2020-04-02
HRP20260155T1 (hr) 2026-03-27
PT3592355T (pt) 2026-02-03
RU2019131757A3 (https=) 2021-05-31
EP4659740A3 (en) 2026-02-18
EP3592355A1 (en) 2020-01-15
US11497750B2 (en) 2022-11-15
TW201842913A (zh) 2018-12-16
US10617693B2 (en) 2020-04-14
EP3592355B1 (en) 2025-12-10
NZ757105A (en) 2026-02-27
RS67713B1 (sr) 2026-02-27
AU2024201828B2 (en) 2026-02-19
US20230172942A1 (en) 2023-06-08
SI3592355T1 (sl) 2026-04-30
BR112019018687A2 (pt) 2020-04-07
EP4659740A2 (en) 2025-12-10
WO2018165647A1 (en) 2018-09-13
MX2019010707A (es) 2020-01-15
FI3592355T3 (fi) 2026-02-13
AU2018231144A1 (en) 2019-10-03
ZA202100106B (en) 2022-08-31
IL269182A (en) 2019-11-28
EP3592355A4 (en) 2021-01-06
RU2019131757A (ru) 2021-04-12
MX387658B (es) 2025-03-18
JP7502863B2 (ja) 2024-06-19
IL269182B1 (en) 2023-07-01
PL3592355T3 (pl) 2026-04-07
CA3055938A1 (en) 2018-09-13
ES3060528T3 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
TWI841523B (zh) 治療及／或預防光化性角化症之方法
Sharma et al. Rosacea management: a comprehensive review
Dhar et al. Intralesional bleomycin in the treatment of cutaneous warts: a randomized clinical trial comparing it with cryotherapy
Gerlero et al. Treatment of warts in children: an update
Barco et al. Rosacea
US9713608B2 (en) Method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
RU2805929C2 (ru) Способы лечения и/или предотвращения актинического кератоза
NZ606177A (en) Compositions for the treatment of actinic keratosis
HK40020549A (en) Kx2‑391/kx‑01 for use in the treatment of actinic keratosis
HK40020549B (en) Kx2‑391/kx‑01 for use in the treatment of actinic keratosis
BR122025000862A2 (pt) Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica
Kumar et al. Novel strategies for effective actinic keratosis treatment: a review
TW202112379A (zh) 治療及／或預防乾癬之方法
EP2849742A1 (en) Method of topically treating actinic keratosis with ingenol mebutate cycle therapy
POSTINFLAMMATORY Tolerability assessment of combination clindamycin/tretinoin hydrogel for the treatment of acne vulgaris in 2219 subjects
TATE Treating cutaneous warts